- Home
- APLT vs SRTS Comparison
APLT vs SRTS Comparison
Compare APLT & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- SRTS
- Stock Information
- Founded
- APLT 2016
- SRTS 2010
- Country
- APLT United States
- SRTS United States
- Employees
- APLT N/A
- SRTS N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- SRTS Medical/Dental Instruments
- Sector
- APLT Health Care
- SRTS Health Care
- Exchange
- APLT Nasdaq
- SRTS Nasdaq
- Market Cap
- APLT 80.3M
- SRTS 88.7M
- IPO Year
- APLT 2019
- SRTS 2016
- Fundamental
- Price
- APLT $0.52
- SRTS $4.77
- Analyst Decision
- APLT Buy
- SRTS Strong Buy
- Analyst Count
- APLT 7
- SRTS 3
- Target Price
- APLT $6.10
- SRTS $13.00
- AVG Volume (30 Days)
- APLT 1.6M
- SRTS 122.0K
- Earning Date
- APLT 05-08-2025
- SRTS 05-08-2025
- Dividend Yield
- APLT N/A
- SRTS N/A
- EPS Growth
- APLT N/A
- SRTS 1266.06
- EPS
- APLT N/A
- SRTS 0.41
- Revenue
- APLT N/A
- SRTS $41,807,000.00
- Revenue This Year
- APLT N/A
- SRTS $9.09
- Revenue Next Year
- APLT $2,426.33
- SRTS $22.30
- P/E Ratio
- APLT N/A
- SRTS $11.71
- Revenue Growth
- APLT N/A
- SRTS 71.31
- 52 Week Low
- APLT $0.43
- SRTS $3.09
- 52 Week High
- APLT $10.62
- SRTS $9.33
- Technical
- Relative Strength Index (RSI)
- APLT 43.47
- SRTS 44.90
- Support Level
- APLT $0.52
- SRTS $4.46
- Resistance Level
- APLT $0.62
- SRTS $4.93
- Average True Range (ATR)
- APLT 0.05
- SRTS 0.20
- MACD
- APLT 0.01
- SRTS 0.09
- Stochastic Oscillator
- APLT 23.19
- SRTS 69.35
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.